Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Aug;36(2):93–98. doi: 10.1111/j.1365-2125.1993.tb04202.x

R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

J H Ahmed 1, J Godden 1, P A Meredith 1, H L Elliott 1
PMCID: PMC1364570  PMID: 8398588

Abstract

1. This study in healthy normotensive male volunteers investigated the pharmacokinetics and the effects on electrocardiographic PR interval, blood pressure and heart rate of single oral doses of the single isomer R-verapamil (250, 500 and 1000 mg) in comparison to placebo and 240 mg racemic verapamil. 2. After 500 and 1000 mg R-verapamil there were significant prolongations in PR interval, maximal at 1-2 h after dosing and coincident with peak plasma drug concentrations, but these were not significantly different from the maximum prolongation obtained with 240 mg racemic verapamil. 3. After 1000 mg R-verapamil there was a significant hypotensive effect, particularly on standing. 4. Single doses of 500 and 1000 mg R-verapamil produced peak plasma drug concentrations in the range 1000-3000 ng ml-1. If this concentration range is appropriate for adjuvant cancer chemotherapy it can be predicted that similar steady state concentrations will occur with a dosage regimen of 300 mg 3 times daily.

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Schwartz J. B., Todd E. L., Luchi R., Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med. 1986 Sep;105(3):329–336. doi: 10.7326/0003-4819-105-3-329. [DOI] [PubMed] [Google Scholar]
  2. Beck W. T. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987 Sep 15;36(18):2879–2887. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  3. Cole S. C., Flanagan R. J., Johnston A., Holt D. W. Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum. J Chromatogr. 1981 Nov 20;218:621–629. doi: 10.1016/s0021-9673(00)82087-7. [DOI] [PubMed] [Google Scholar]
  4. Echizen H., Brecht T., Niedergesäss S., Vogelgesang B., Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J. 1985 Feb;109(2):210–217. doi: 10.1016/0002-8703(85)90585-x. [DOI] [PubMed] [Google Scholar]
  5. Echizen H., Vogelgesang B., Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther. 1985 Jul;38(1):71–76. doi: 10.1038/clpt.1985.137. [DOI] [PubMed] [Google Scholar]
  6. Freedman S. B., Richmond D. R., Ashley J. J., Kelly D. T. Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin Pharmacol Ther. 1981 Nov;30(5):644–652. doi: 10.1038/clpt.1981.216. [DOI] [PubMed] [Google Scholar]
  7. Harker W. G., Bauer D., Etiz B. B., Newman R. A., Sikic B. I. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res. 1986 May;46(5):2369–2373. [PubMed] [Google Scholar]
  8. Hill B. M. Preparation for retirement. Br Dent J. 1969 Mar 4;126(5):235–236. [PubMed] [Google Scholar]
  9. Merry S., Flanigan P., Schlick E., Freshney R. I., Kaye S. B. Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer. 1989 Jun;59(6):895–897. doi: 10.1038/bjc.1989.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Neugebauer G. Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog. Cardiovasc Res. 1978 Apr;12(4):247–254. doi: 10.1093/cvr/12.4.247. [DOI] [PubMed] [Google Scholar]
  11. Ozols R. F., Cunnion R. E., Klecker R. W., Jr, Hamilton T. C., Ostchega Y., Parrillo J. E., Young R. C. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987 Apr;5(4):641–647. doi: 10.1200/JCO.1987.5.4.641. [DOI] [PubMed] [Google Scholar]
  12. Schwartz J. B., Verotta D., Sheiner L. B. Pharmacodynamic modeling of verapamil effects under steady-state and nonsteady-state conditions. J Pharmacol Exp Ther. 1989 Dec;251(3):1032–1038. [PubMed] [Google Scholar]
  13. Sheiner L. B., Stanski D. R., Vozeh S., Miller R. D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 Mar;25(3):358–371. doi: 10.1002/cpt1979253358. [DOI] [PubMed] [Google Scholar]
  14. Tsuruo T., Iida H., Nojiri M., Tsukagoshi S., Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res. 1983 Jun;43(6):2905–2910. [PubMed] [Google Scholar]
  15. Wagner J. G. Predictability of verapamil steady-state plasma levels from single-dose data explained. Clin Pharmacol Ther. 1984 Jul;36(1):1–4. doi: 10.1038/clpt.1984.129. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES